Nicolas Voirin

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8768547/publications.pdf

Version: 2024-02-01

304368 3,829 48 22 h-index citations papers

48 g-index 49 49 49 4467 docs citations times ranked citing authors all docs

205818

#	Article	IF	CITATIONS
1	COVID-19 outbreaks in nursing homes: A strong link with the coronavirus spread in the surrounding population, France, March to July 2020. PLoS ONE, 2022, 17, e0261756.	1.1	7
2	UVEITIS TREATED WITH DEXAMETHASONE IMPLANT. Retina, 2021, 41, 620-629.	1.0	11
3	LONG-TERM INCIDENCE AND RISK FACTORS OF OCULAR HYPERTENSION FOLLOWING DEXAMETHASONE-IMPLANT INJECTIONS. Retina, 2021, 41, 1438-1445.	1.0	27
4	Seasonality of confirmed malaria cases from 2008 to 2017 in Togo: a time series analysis by health district and target group. BMC Infectious Diseases, 2021, 21, 1189.	1.3	4
5	Optimizing Strategies for Chlamydia trachomatis and Neisseria gonorrhoeae Screening in Men Who Have Sex With Men: A Modeling Study. Clinical Infectious Diseases, 2020, 70, 1966-1972.	2.9	7
6	Long-term follow-up of diabetic macular edema treated with dexamethasone implant: a real-life study. Acta Diabetologica, 2020, 57, 1413-1421.	1.2	12
7	Changes in registered malaria cases and deaths in Togo from 2008 to 2017. International Journal of Infectious Diseases, 2020, 101, 298-305.	1.5	7
8	Incidence of Irvine Gass Syndrome after Phacoemulsification with Spectral-Domain Optical Coherence Tomography. Ocular Immunology and Inflammation, 2019, 27, 1224-1231.	1.0	15
9	Influenza surveillance during the 2009â€2010, 2010â€2011, 2011â€2012, and 2012â€2013 seasons in Algeria. Jof Medical Virology, 2019, 91, 1394-1399.	ournal 2.5	3
10	EVALUATION OF OBSTRUCTIVE SLEEP APNEA SYNDROME AS A RISK FACTOR FOR DIABETIC MACULAR EDEMA IN PATIENTS WITH TYPE II DIABETES. Retina, 2019, 39, 274-280.	1.0	23
11	The Pattern of Recurrence in Diabetic Macular Edema Treated by Dexamethasone Implant: The PREDIAMEX Study. Ophthalmology Retina, 2018, 2, 567-573.	1.2	22
12	Evaluation of Efficacy and Safety of Dexamethasone Intravitreal Implants of Vitrectomized and Nonvitrectomized Eyes in a Real-World Study. Journal of Ocular Pharmacology and Therapeutics, 2018, 34, 596-602.	0.6	15
13	Effectiveness and safety of dexamethasone implants for postsurgical macular oedema including Irvine–Gass syndrome: the EPISODIC-2 study. British Journal of Ophthalmology, 2017, 101, bjophthalmol-2016-308544.	2.1	52
14	REAL-LIFE STUDY IN DIABETIC MACULAR EDEMA TREATED WITH DEXAMETHASONE IMPLANT. Retina, 2017, 37, 753-760.	1.0	99
15	Survival of solid cancer patients in France, 1989–2013: a population-based study. European Journal of Cancer Prevention, 2017, 26, 461-468.	0.6	47
16	SAFETY OF INTRAVITREAL DEXAMETHASONE IMPLANT (OZURDEX). Retina, 2017, 37, 1352-1359.	1.0	120
17	TOLERANCE OF INTRAVITREAL DEXAMETHASONE IMPLANTS IN PATIENTS WITH OCULAR HYPERTENSION OR OPEN-ANGLE GLAUCOMA. Retina, 2017, 37, 173-178.	1.0	14
18	Contacts between health care workers and patients in a short-stay geriatric unit during the peak of a seasonal influenza epidemic compared with a nonepidemic period. American Journal of Infection Control, 2016, 44, 905-909.	1.1	5

#	Article	IF	Citations
19	Effectiveness and safety of dexamethasone implants for post-surgical macular oedema including Irvine-Gass syndrome: the EPISODIC study. British Journal of Ophthalmology, 2015, 99, 979-983.	2.1	53
20	Combining High-Resolution Contact Data with Virological Data to Investigate Influenza Transmission in a Tertiary Care Hospital. Infection Control and Hospital Epidemiology, 2015, 36, 254-260.	1.0	83
21	Detection of hospital outbreaks of influenza-like illness based on excess of incidence rates compared to the community. American Journal of Infection Control, 2014, 42, 1325-1327.	1.1	13
22	Effect of Standardized Surveillance of Intensive Care Unit–Acquired Infections on Ventilator-Associated Pneumonia Incidence. Infection Control and Hospital Epidemiology, 2014, 35, 1290-1293.	1.0	7
23	Correlation between emergency room visits for influenza-like illness during the influenza A (H1/N1) pandemic in children and adults. Influenza and Other Respiratory Viruses, 2013, 7, 364-366.	1.5	O
24	Estimation of the incubation period of invasive aspergillosis by survival models in acute myeloid leukemia patients. Medical Mycology, 2013, 51, 214-218.	0.3	12
25	Estimating Potential Infection Transmission Routes in Hospital Wards Using Wearable Proximity Sensors. PLoS ONE, 2013, 8, e73970.	1.1	266
26	Prevalence and risk factors for HIV, hepatitis B virus, and syphilis among pregnant women in Mayotte, Indian Ocean, 2008–2009. International Journal of Gynecology and Obstetrics, 2012, 119, 61-65.	1.0	7
27	Invasive aspergillosis in patients with hematologic malignancies: incidence and description of 127 cases enrolled in a single institution prospective survey from 2004 to 2009. Haematologica, 2011, 96, 1685-1691.	1.7	63
28	High-Resolution Measurements of Face-to-Face Contact Patterns in a Primary School. PLoS ONE, 2011, 6, e23176.	1.1	552
29	Low monocyte human leukocyte antigen-DR is independently associated with nosocomial infections after septic shock. Intensive Care Medicine, 2010, 36, 1859-1866.	3.9	234
30	Proatrial natriuretic peptide is a better predictor of 28-day mortality in septic shock patients than proendothelin-1. Clinical Chemistry and Laboratory Medicine, 2010, 48, 1813-1820.	1.4	10
31	The p-control chart: a tool for care improvement. International Journal for Quality in Health Care, 2010, 22, 402-407.	0.9	55
32	Estimating Attributable Mortality Due to Nosocomial Infections Acquired in Intensive Care Units. Infection Control and Hospital Epidemiology, 2010, 31, 388-394.	1.0	35
33	Assessment of pro-vasopressin and pro-adrenomedullin as predictors of 28-day mortality in septic shock patients. Intensive Care Medicine, 2009, 35, 1859-1867.	3.9	621
34	Contribution of cell culture, RNA extraction, and reverse transcription to the measurement error in quantitative reverse transcription polymerase chain reaction-based gene expression quantification. Analytical Biochemistry, 2009, 393, 29-35.	1.1	6
35	Reduction of urinary tract infections acquired in an intensive care unit during a 10-year surveillance program. European Journal of Epidemiology, 2008, 23, 641-645.	2.5	8
36	Nosocomial Infection After Septic Shock Among Intensive Care Unit Patients. Infection Control and Hospital Epidemiology, 2008, 29, 1054-1065.	1.0	57

#	Article	IF	CITATIONS
37	Cannabis Smoking and Risk of Lung Cancer in Men: A Pooled Analysis of Three Studies in Maghreb. Journal of Thoracic Oncology, 2008, 3, 1398-1403.	0.5	102
38	Decreased Expression of the Fractalkine Receptor CX3CR1 on Circulating Monocytes as New Feature of Sepsis-Induced Immunosuppression. Journal of Immunology, 2008, 180, 6421-6429.	0.4	106
39	Is There a Role for Pelvic Irradiation in Localized Prostate Adenocarcinoma? Preliminary Results of GETUG-01. Journal of Clinical Oncology, 2007, 25, 5366-5373.	0.8	311
40	Soluble human leukocyte antigen-G5 in septic shock: Marked and persisting elevation as a predictor of survival. Critical Care Medicine, 2007, 35, 1942-1947.	0.4	30
41	Progression to cirrhosis in hepatitis C patients: an age-dependent process. Liver International, 2007, 27, 335-339.	1.9	75
42	Prognosis of early-onset breast cancer based on BRCA1/2 mutation status in a French population-based cohort and review. Breast Cancer Research and Treatment, 2007, 101, 233-245.	1.1	47
43	Persisting low monocyte human leukocyte antigen-DR expression predicts mortality in septic shock. Intensive Care Medicine, 2006, 32, 1175-1183.	3.9	442
44	Primary care physicians' behaviors towards risk of iatrogenesis in elderly patients. European Journal of Clinical Pharmacology, 2006, 62, 563-570.	0.8	5
45	Risk of lung cancer and past use of cannabis in Tunisia. Journal of Thoracic Oncology, 2006, 1, 577-9.	0.5	21
46	Longitudinal study of cytokine and immune transcription factor mRNA expression in septic shock. Clinical Immunology, 2005, 114, 61-69.	1.4	87
47	The predictive value of core antigen testing for the management of hepatitis C patients receiving pegylated interferon/ribavirin treatment. Journal of Medical Virology, 2004, 73, 392-396.	2.5	18
48	Effects of co-infection with hepatitis C virus and GB virus C on CD4 cell count and HIV-RNA level among HIV-infected patients treated with highly active antiretroviral therapy. Aids, 2002, 16, 1556-1559.	1.0	11